These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20545952)

  • 21. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efalizumab-associated papular psoriasis.
    Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
    Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efalizumab therapy for psoriasis in patients with inadequate responses to etanercept.
    Kramer JM; Turner JE
    Am J Clin Dermatol; 2009; 10(2):134-40. PubMed ID: 19222255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
    Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
    Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
    Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
    Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases.
    Antonucci A; Bardazzi F; Balestri R; Patrizi A
    J Dermatolog Treat; 2009; 20(1):61-2. PubMed ID: 18618361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
    Berends MA; Driessen RJ; Langewouters AM; Boezeman JB; Van De Kerkhof PC; De Jong EM
    J Dermatolog Treat; 2007; 18(2):76-83. PubMed ID: 17520463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efalizumab--therapy of moderately severe to severe plaque-psoriasis in the dermatologist's practice].
    Dirschka T; Reinhold U; Rosenbach T; Schubert E; Sebastian M; Streit V
    J Dtsch Dermatol Ges; 2006 Oct; 4 Suppl 1():S3-S12. PubMed ID: 17022742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy.
    Kircik LH; Liu C; Goffe BS
    J Drugs Dermatol; 2008 Oct; 7(10):947-52. PubMed ID: 19112758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
    Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
    J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
    Schön MP
    Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case reports: efalizumab-associated lymphoproliferative disease.
    Bommakanti S; Patil A; Eshoa C; Chitambar CR
    J Drugs Dermatol; 2007 Jun; 6(6):646-8. PubMed ID: 17668531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation.
    Bukhari IA
    Saudi Med J; 2007 Nov; 28(11):1745-7. PubMed ID: 17965804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efalizumab.
    Chacko M; Weinberg JM
    Dermatol Ther; 2007; 20(4):265-9. PubMed ID: 17970891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rebound of psoriasis during treatment with efalizumab.
    Golda N; Benham SM; Koo J
    J Drugs Dermatol; 2006 Jan; 5(1):63-5. PubMed ID: 16468294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
    Myers WA; Najarian D; Gottlieb AB
    J Dermatolog Treat; 2006; 17(6):353-4. PubMed ID: 17853308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current concepts and review of efalizumab in the treatment of psoriasis.
    Leonardi CL
    Dermatol Clin; 2004 Oct; 22(4):427-35, ix. PubMed ID: 15450338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
    Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
    Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.